Inside TumorSight Risk: What MRI-Based Recurrence Assessment Can and Cannot Tell Clinicians
Dr. Dereck Mush, MD, MBARobin Shah
Co-Founder and CEO, Thyme Care
- Industry
- Value-based oncology care
- Based in
- Nashville, USA
- Company funding
- $300M raised
- Region
- North America
Oncology care executive, previously at Flatiron Health and OneOncology.
Leads Thyme Care past a $2 billion valuation after a $125M Series E backed by Morgan Health, Humana and CVS Health Ventures.
[]
More founders in Value-based oncology care
- Dr. Bobby Green
Thyme Care
Related on The Signal
Dr. Dereck Mush, MD, MBA
Overcoming the Solvent Front: How Jideytro Validates Nuvalent's Precision Oncology Playbook
Dr. Dereck Mush, MD, MBA
Inside SimBioSys TumorSight Risk: Bringing Recurrence Assessment Into the MRI Workflow
Dr. Dereck Mush, MD, MBA
Reversing the Resistance Cascade: Vascular Reprogramming and Second-Line Antiandrogen Synergy
Dr. Dereck Mush, MD, MBAKeep exploring